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Abstract
Theranostic systems capable of delivering imaging and therapeutic agents at a specific target are the
focus of intense research efforts in drug delivery. To overcome non-degradability and toxicity
concerns of conventional theranostic systems, we formulated a novel thermo-responsive
fluorescent polymer (TFP) and conjugated it on the surface of iron oxide magnetic nanoparticles
(MNPs) for imaging and therapeutic applications in solid tumors. Methods: TFP-MNPs were
synthesized by copolymerizing poly(N-isopropylacrylamide), allylamine and a biodegradable
photoluminescent polymer, and conjugating it on MNPs via a free radical polymerization reaction.
Physicochemical properties of the nanoparticles were characterized using Fourier transform
infrared spectroscopy, dynamic light scattering, and vibrational sample magnetometry. Nanoparticle
cytocompatibility, cellular uptake and cytotoxicity were evaluated using in vitro cell assays. Finally, in
vivo imaging and therapeutic efficacy studies were performed in subcutaneous tumor xenograft
mouse models. Results: TFP-MNPs of ~135 nm diameter and -31 mV ζ potential maintained
colloidal stability and superparamagnetic properties. The TFP shell was thermo-responsive,
fluorescent, degradable, and released doxorubicin in response to temperature changes. In vitro cell
studies showed that TFP-MNPs were compatible to human dermal fibroblasts and prostate
epithelial cells. These nanoparticles were also taken up by prostate and skin cancer cells in a
dose-dependent manner and exhibited enhanced killing of tumor cells at 41°C. Preliminary in vivo
studies showed theranostic capabilities of the nanoparticles with bright fluorescence, MRI signal, and
therapeutic efficacy under magnetic targeting after systemic administration in tumor bearing mice.
Conclusion: These results indicate the potential of TFP-MNPs as multifunctional theranostic
nanoparticles for various biological applications, including solid cancer management.
Key words: theranostic systems; thermo-responsive polymers; photoluminescent polymers; solid tumors;
magnetic nanoparticles

Introduction
Theranostic drug delivery systems are attractive
platforms comprising diagnostic and therapeutic

agents for simultaneous imaging and therapy in a
single setting. Theranostic systems can potentially
http://www.ntno.org
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assist in non-invasive monitoring of both the disease
progression and nanoparticle drug delivery route [1].
Stimuli-responsive polymers and imaging agents (e.g.
quantum dots, organic dyes or iron oxide
nanoparticles)
are
attractive
candidates
for
formulating theranostic systems, as they can be
tracked following administration and provide
controlled drug release in response to external stimuli.
However,
these
systems
are
limited
by
non-biodegradability of polymers and by toxicity,
photobleaching and possible leaching-out of the
imaging agents [2]. To overcome these limitations,
biodegradable photoluminescent materials have been
developed from diverse materials such as porous
silicon
nanostructures,
conjugated
polymeric
nanoparticles containing π conjugated electron
systems, and combinations of polyethylene glycol,
citric acid, aliphatic diols and amino acid based
polymers for in vivo biomedical applications such as
tumor imaging and tracking the degradation progress
of implanted scaffold materials [3-6]. The
degradability of these polymers and the superior
photoluminescent properties such as high quantum
yield, photobleaching resistance, and tunable
emission up to near infrared region, make them
unique for trackable drug delivery systems.
Moreover, these polymers have demonstrated
excellent compatibility and imaging ability both in
vitro [7] and in vivo [5].
Thermo-responsive polymers have long been
studied for drug delivery applications due to their
attractive temperature-dependent drug release
behavior. Poly(N-isopropylacrylamide) (PNIPAAm)
and its copolymers are the most commonly used
thermo-responsive polymers for such applications [8,
9]. PNIPAAm undergoes a reversible phase-transition
at a characteristic lower critical solution temperature
(LCST) of 32°C [10-12]. At temperatures below the
LCST, the polymer becomes hydrophilic and swells
by absorbing large quantities of water; whereas at
temperatures higher than the LCST, the interactions
among hydrophobic groups increase, causing the
polymer to become hydrophobic by shrinking and
releasing the payload. PNIPAAm is usually
copolymerized with hydrophilic monomers such as
acrylamide to increase the LCST above body
temperature for controlled drug delivery applications
as well as with monomers such as allylamine (AH) to
provide amine functional groups for bioconjugation
applications [13]. Despite PNIPAAm’s immense
potential in the field of drug delivery and biomedical
sciences,
it
suffers
the
disadvantage
of
non-degradability, which may cause inflammatory
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and toxic responses due to the prolonged presence of
the polymer in the body [10, 11, 14]. This limitation
has provided the motivation for several research
groups to develop biodegradable and temperaturesensitive PNIPAAm-based copolymers for drug
delivery applications [15-17].
In the current work, we have developed a
copolymer of PNIPAAm, AH, and a previously
developed water soluble biodegradable photoluminescent polymer (WBPLP) [5] to form a novel
thermo-responsive fluorescent polymer (TFP), and
subsequently formulated the nanoparticles (TFP NPs).
The unique combination of WBPLP and PNIPAAm
may enable nanoparticle tracking in vivo using
fluorescence imaging, while providing controlled and
temperature-dependent release of the encapsulated
payload. The presence of WBPLP in the copolymer
may also elevate the LCST of the PNIPAAm due to
added hydrophilic content in the polymer backbone,
thus eliminating commonly used toxic acrylamide
monomers to increase the LCST.
Another aspect of our work was the utilization of
superparamagnetic iron oxide nanoparticles as core
materials to coat the TFP polymer on. Iron oxide
magnetic nanoparticles (MNPs) are usually 10-100 nm
in size and by virtue of their magnetic property can be
recruited at a specific site in vivo. The superparamagnetic nature of iron oxide nanoparticles makes them
efficient T2 weighted magnetic resonance imaging
(MRI) contrast agents that can be applied as imaging
probes for early tumor detection [18]. These attributes
make MNPs potentially useful for tumor imaging as
well as magnetic and image guided drug delivery [19,
20]. This is highly beneficial in limiting the uptake of
toxic chemotherapeutic molecules by healthy cells,
thus improving drug delivery efficacy [21]. Despite
the immense potential of MNPs for tumor diagnosis
and therapy, there remain a limited number of
MNPs-based formulations approved for clinical use
[22], possibly due to their reactive surface mediated
toxicity. The proposed TFP polymer coating on iron
oxide nanoparticles may help alleviate iron oxide
toxicity and make an improved magnetic nanoparticle
system. In addition, the TFP would provide
fluorescent signals for optical imaging, making a
multi-modal imaging system for enhanced imaging
and diagnosis. Thus, we investigated TFP-coated
MNPs (TFP-MNPs) core-shell system for potential
magnetic targeting, multi-modal (optical and MRI)
imaging, and simulated magnetic hyperthermia
applications, so that both diagnosis and treatment of
the disease is possible in a single setting.

http://www.ntno.org
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Materials and Methods
Materials
All
chemicals
were
purchased
from
Sigma-Aldrich (St. Louis, MO) and used without
further modification. All cell lines were purchased
from ATCC (Manassas, VA), and Dulbecco’s modified
Eagle’s medium (DMEM), trypsin EDTA, fetal bovine
serum (FBS), and penicillin-streptomycin were
purchased from Invitrogen (Carlsbad, CA) and used
for in vitro cell culture studies.

Synthesis of fluorescent polymer
WBPLP was synthesized following our
previously developed protocols [5]. Briefly, equimolar
ratios of citric acid and 1,8-octane diol were combined
with L-cysteine, while keeping the L-cysteine to citric
acid ratio at 0.8. The mixture was melted at 160°C for
20 minutes, subsequently cooled to 140°C and reacted
for an additional 75 minutes to form BPLP-Cysteine
oligomers. The BPLP-Cysteine oligomers were
collected via precipitation using a water/1-4 dioxane
mixture and were later freeze dried and subsequently
combined with polyethylene glycol and amino acids
to form water soluble BPLP (WBPLP).

Copolymerization of WBPLP and AH
WBPLP was then conjugated with AH using
carbodiimide chemistry [23]. In brief, WBPLP (45 mg)
was dissolved in 2-(N-morpholino) ethanesulphonic
acid (MES) buffer (5 ml), followed by the addition of
1-Ethyl-3-(3-dimethylaminopropyl)
carbodiimide
(EDC) and N-Hydroxy Succinimide (NHS) (1:1). After
30 minutes of mixing on a rotator, AH (18.75 µl) was
added and the reaction was continued for 12 hours at
room temperature. The WBPLP-AH copolymer was
then dialyzed using 500 Da molecular weight cut-off
dialysis membranes (Spectrum Laboratories Inc,
Rancho Dominguez, CA) for 24 hours to remove the
unreacted chemicals.

Synthesis of TFP NPs
To generate TFP NPs, WBPLP-AH was then
copolymerized
with
N-isopropylacrylamide
(NIPAAm) by radical polymerization in the presence
of a crosslinker. In brief, the purified WBPLP-AH
solution (5 ml) and NIPAAm (45 mg) were dissolved
in deionized (DI) water (25 ml). Crosslinker,
N,N’-Methylenebisacryamide (BIS, 5.85 mg) and
surfactant, sodium dodecyl sulphate (SDS, 17.4 mg)
were added to the mixture, while continuously
stirring for 30 minutes. Ammonium persulphate
(APS, 52.48 mg) and tetramethylethylenediamine
(TEMED, 69 µl) were then added to initiate the radical
polymerization, and the reaction was stirred for 4

3
hours under nitrogen at room temperature. The
formed nanoparticle solution was dialyzed using 3500
Da molecular weight cut-off dialysis membranes for
24 hours to remove free surfactants and unreacted
chemicals.

Synthesis of TFP-MNPs
TFP-MNPs were synthesized using silanefunctionalized MNPs (silane-MNPs) as templates for
TFP conjugation. Silane-MNPs were synthesized by
dispersing MNPs in 99% ethanol by sonication (50 W,
5 minutes), followed by the addition of acetic acid (2
ml). After 5 minutes of further sonication, the reaction
was transferred to a stir plate and vinyltrimethoxysilane (0.49 ml) was added. The reaction was
carried out for 24 hours at room temperature.
Silane-MNPs were then washed several times with
99% ethanol and collected using a magnet. To prepare
the TFP-MNPs, silane-MNPs (10 mg) were sonicated
in DI water (25 ml) at 50 W for 10 minutes. The
purified WBPLP-AH (100 mg), NIPAAm (45 mg), BIS
(5.85 mg) and SDS (17.4 mg) were added to the
reaction while sonicating. The reaction was then
transferred to a stir plate, and APS (52.48 mg) and
TEMED (69 µl) were added to the reaction with
vigorous stirring. The reaction was carried out under
nitrogen for 4 hours at room temperature. The
TFP-MNPs were collected by a magnet and washed
several times with DI water to remove surfactants and
unreacted chemicals.

Physicochemical characterization
Particle size, morphology, polydispersity index
(PDI), and surface charge (ζ potential) were evaluated
using transmission electron microscopy (TEM;
Technai, JEOL 1200 EX, Tokyo, Japan) and dynamic
light scattering (DLS; ZetaPals, Brookhaven
Instrument, Holtsville, NY). To prepare samples for
TEM, a drop of nanoparticle solution was put on the
surface of a Formvar coated 200-mesh copper grid
(Electron Microscopy Sciences, Hatfield, PA) and
air-dried before loading onto a microscope. For DLS, 1
mg/ml nanoparticle solution was directly added to a
cuvette for size, polydispersity and surface charge
measurements. Next, Fourier transform infrared
spectroscopy (FTIR; Nicolet 6700 FT-IR spectrometer,
Thermo Fisher Scientific, Madison, WI) was
performed to analyze characteristic peaks associated
with the chemical bonds in the polymer chain. All
FTIR samples were purified, lyophilized powders.
The LCST of the TFP NPs was also determined
quantitatively by heating the nanoparticle solution in
1°C increments from room temperature up to 45°C in
a glass cuvette, and by measuring the absorbance of
the nanoparticle solution at 500 nm wavelength using
http://www.ntno.org
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UV-Vis spectrophotometry (Biorad, SmartSpec Plus,
Life Science Research, Hercules, CA).
Nanoparticle stability and degradation were
studied at physiological conditions. To study particle
stability, the TFP-MNPs were incubated in phosphate
buffered saline (PBS) or 10% FBS solution at 37°C and
the particle size was measured up to 72 hours using
DLS. To study the degradation of the TFP shell,
TFP-MNPs were suspended in DI water and
incubated at 37°C over a period of time. At each time
point, nanoparticles were collected by a magnet, and
dry weight of the nanoparticles was recorded. A
relative percentage of dry weights of the
nanoparticles at all the time points were calculated
with respect to the initial dry weight of the
nanoparticles.

Magnetic characterization
The iron content in the nanoparticles was
evaluated using iron assays as described previously
[24]. Briefly, 100 µl of the nanoparticle solution was
incubated with 50% (v/v) hydrochloric acid at 37°C
overnight. Subsequently, APS solution (1 mg/ml) and
0.1 M potassium thiocyanate solution were added
with 15 minutes incubation between each step. The
absorbance readings of the samples were taken at 520
nm using a UV-Vis spectrophotometer (Infinite M200
plate reader, Tecan, Durham, NC). Additionally,
magnetic recruitment of the TFP-MNPs were tested in
the presence of an external magnet and compared
with the TFP-MNPs suspension in the absence of the
external magnet.
The magnetic properties of TFP-MNPs were
analyzed using a vibrating sample magnetometer
(VSM, KLA-Tencor EV7, San Jose, CA) and compared
to those of bare MNPs. The samples consisting of
equal amounts of iron were embedded in wax and
hysteresis loops were obtained by varying the
magnetic fields at room temperature. Then MR
imaging was done on agarose phantoms containing
varying concentrations of TFP-MNPs (0, 0.25, 0.5, 1
and 2 mg/ml). Agarose phantoms containing TFP
NPs (without MNPs) were imaged as negative
control. T2 weighted images were acquired using TR:
2500 ms, TE: 10 ms, FOV: 40x40 mm, and with a slice
thickness of 1 mm.

Fluorescence characterization
The fluorescence from the nanoparticles was
observed in UV light. The positive control contained
WBPLP solution and the negative control contained
PNIPAAm-AH solution. Furthermore, the effect of
temperature on the fluorescence intensity of the
nanoparticles was investigated. Briefly, the TFP NPs
(3 mg/ml) in a tube were immersed in a water tank
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that was heated using a temperature controller. The
sample was excited with a blue laser (473 nm) and the
emitted light was passed through a 532 nm long pass
filter. The fluorescence intensity was recorded as
voltage read out from a high-speed digital
oscilloscope. The measurements were taken at
temperatures ranging from 25°C to 45°C with an
increase of 0.5°C. The fluorescence intensities of these
measurements were then converted to the percentage
lost in the fluorescence intensity as a function of
temperature.

Drug loading and release
For drug loading and release studies,
hydrophilic doxorubicin hydrochloride (Dox; Tocris
Bioscience, Ellisville, MO) was used as an anti-cancer
drug model. Freeze-dried TFP-MNPs (10 mg) were
suspended in Dox (0.02% w/v in PBS) solution and
incubated at 4°C for 3 days, with gentle stirring to
allow loading of the drug into the nanoparticles by
virtue of the drug absorption via polymer swelling at
low temperatures. After 3 days, the Dox-loaded
TFP-MNPs (Dox-TFP-MNPs) were separated using a
magnet (1.3 T) and the supernatant was collected to
determine the Dox encapsulation efficiency using the
following formula:
Encapsulation efficiency (%)
(Initial drug amount − Supernatant drug amount)
∗ 100
=
Initial drug amount

To study thermo-responsive drug release, the
Dox-TFP-MNPs were incubated at 25°C (room
temperature,
<
LCST),
37°C
(physiological
temperature, < LCST), or 41°C (> LCST) in PBS. At
predetermined time points, an external magnet was
used to separate the nanoparticles in each of the three
groups, and 1 ml of the supernatant was collected.
The same volume was replenished with fresh PBS.
Dox concentrations in the collected samples were
measured by UV-Vis spectrofluorometer at 470 nm
excitation and 585 nm emission wavelengths and
calculated using a Dox standard curve.

In vitro cell studies
For cytocompatibility studies, human dermal
fibroblasts (HDFs) and normal prostate epithelial cells
(PZ-HPV-7) were seeded in a 96-well plate at a
density of 5000 cells/well and maintained at 37°C and
5% CO2 for 24 hours. The culture medium was
replaced
with
media
containing
increasing
concentrations of TFP-MNPs (0, 50, 100, 200, 300, and
500 µg/ml) and the cells were incubated for 12 and 24
hours. Cells exposed to media only served as positive
controls. The cell viability was determined at each
time point using cell viability MTS assays (CellTiter 96
http://www.ntno.org
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Aqueous One Solution Cell Proliferation Assay,
Promega, Madison, WI) following the manufacturer’s
instructions.
Cellular uptake of nanoparticles was studied on
A431 and G361 skin cancer cells as well as on PC3 and
LNCaP prostate cancer cells. First, the cells were
seeded in a 96-well plate as described earlier.
Following overnight incubation at 37°C, the media
was replaced with different concentrations of
TFP-MNPs (0, 50, 100, 200, 300, and 500 µg/ml)
prepared in RPMI-1640 and the well plate was
incubated for 2 hours. Cells that were not exposed to
nanoparticles served as controls. Following
incubation, the cells were washed with PBS three
times and then lysed using 1X Triton. The contents in
the wells were then analyzed using iron assay and
Picogreen DNA assay (Invitrogen, Carlsbad, CA) to
quantify the nanoparticle amount and cell protein
content per well.
For cancer cell killing studies, skin cancer cells
(A431, G361) and prostate cancer cells (PC3) were
seeded at a density of 5000 cells/well in 96-well plates
and incubated overnight at 37°C to facilitate cell
attachment. The following day, the cell media was
aspirated, and the cells were treated with media only,
free Dox, Dox-TFP-MNPs or empty TFP-MNPs. Free
Dox was dosed at the IC50 value of the drug with
respect to each of the cell lines (37 nM for A431, 32 nM
for G361, and 258 nM for PC3 cells). The dose of
Dox-TFP-MNPs was then calculated as the
concentration of nanoparticles which would release a
cumulative IC50 dose of Dox in 24 hours. The empty
TFP-MNPs were dosed at the same concentration as
Dox-TFP-MNPs. The treated cells were incubated at
37°C or 41°C for 24 hours. The cell viability was then
quantified by MTS assays.

In vivo animal studies
All in vivo studies were conducted in compliance
with the guidelines set by the University of Texas at
Arlington and the University of Texas Southwestern
Institutional Animal Care and Use Committees. NOD
SCID mice (6-8 weeks old males) purchased from the
University of Texas Southwestern mouse breeding
core were used for in vivo studies. Prostate cancer
xenograft models were developed by injecting
subcutaneously into both flanks of the animal, DAB2
interactive protein knockdown (KD) prostate cancer
cells (PC3-KD) (~5x105 cells/site), as described
elsewhere [25]. The mice were observed periodically,
and the experiments were performed when the
tumors were palpable.
For fluorescence imaging, BPLP-MNPs (100 μl of
5 mg Fe/kg), TFP-MNPs (100 μl of 5 mg Fe/kg), or
TFP NPs (100 μl of 3 mg/ml) were injected
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intra-tumorally. BPLP-MNPs were used as control
nanoparticles and were synthesized as described
elsewhere [7]. The flank tumors were then imaged
using an in vivo Kodak imaging system (Carestream
Health Inc., Rochester, NY). The relative fluorescence
intensity from the tumors injected with nanoparticles
was calculated by subtracting the fluorescence
intensity of the tumors that were not injected with the
nanoparticles.
For MRI studies, a baseline MRI was obtained on
flank tumors by T2 weighted imaging (TR = 2500 ms,
TEeff = 60 ms, FOV = 40x40 mm, slice thickness = 1
mm). Then saline and TFP-MNPs (1 mg) with or
without magnetic targeting were injected via the tail
vein and MR images were taken 24 hours later. The
difference in MRI signal intensity between the groups
was then analyzed using Image J.
For in vivo therapeutic efficacy study, C57BL6
mice were injected with B16F10 skin cancer cells in the
flanks. When the tumors grew 8-10 mm3 in volume,
saline, free Dox (40 µg/ml, 200 µl), empty TFP-MNPs
(0.8 mg/ml, 200 µl) or Dox-TFP-MNPs (0.8 mg/ml,
200 µl) were intravenously injected. The animals were
then placed on a heating pad at 37°C for 30 min with a
1.3 T magnet placed near the tumors to magnetically
recruit nanoparticles in the region. The animals were
then allowed to return to their cages. At each
predetermined time point, the tumor volumes were
measured using Vernier caliper. On day 15, the
surviving animals were sacrificed and the tumor
volumes were recorded.

Statistical analysis
The results obtained were analyzed using
one-way analysis of variance with p < 0.05 and post
hoc comparisons. All the experiments were repeated
multiple (at least two) times with a sample size of four
(n=4). All the results were presented as
mean ± standard deviation if not specified.

Results
Physicochemical characterization
The copolymerization of WBPLP-AH and
PNIPAAM, and their incorporation into the TFP NPs
and TFP-MNPs was confirmed via FTIR analysis
(Figure 1A). The FTIR spectrum of NIPAAm showed
characteristic peaks corresponding to C=O (1730 cm-1)
and N-C=O (1590 cm-1) bonds. WBPLP-AH spectrum
had peaks corresponding to CH2 (3015 cm-1), -OH
stretching (3496.2 cm-1) and CO-NH (1704 cm-1) bond,
which confirmed the successful conjugation of AH to
the WBPLP. The FTIR spectrum of TFP NPs retained
the peaks corresponding to CH2 groups (3010 cm-1)
from WBPLP-AH and CO-NH (1635 cm-1) and C=O
http://www.ntno.org
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(1705 cm-1) bonds from NIPAAm. The TFP-MNPs
spectrum also showed the presence of these bonds in
addition to the Fe3O4 (540 cm-1) peak, confirming the
incorporation of MNPs. These findings were in
agreement with our previous observations confirming
the presence of MNPs [10] and all the corresponding
bonds from WBPLP and PNIPAAm coatings [5, 26].
Hydrodynamic diameter, PDI and ζ potential of
the TFP NPs was ~150 nm, 0.28 and -13.4 mV,
respectively while that of TFP-MNPs was ~135 nm,
0.07 and -31.0 mV, respectively (Table 1). The TEM
images showed MNPs as dark circular particles and
the TFP NPs appeared as lighter polymeric particles
(Figure 1B). The TFP-MNPs showed a dark magnetic
core and a lighter polymeric shell in their structure.
Stability studies indicate that the TFP-MNPs varied by
less than 15 % of their original size in PBS and 10%
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FBS solution at 37°C over a period of 72 hours (Figure
1C). These results indicate that the nanoparticles are
stable and would likely not aggregate under
physiological conditions. Furthermore, the phase
transition behavior of TFP NPs was characterized by
measuring absorbance (λmax = 500 nm) of the
nanoparticle solutions at each unit increment in
temperature using a UV-Vis spectrophotometer. The
LCST of the nanoparticles (39°C) was evaluated at the
solution temperature where the transmittance drops
to 50% of initial value (Figure 1D). At temperatures
below LCST, the polymer was hydrophilic, making
the solution clear. The solution turned turbid when
the polymer became hydrophobic at temperatures
equal to or greater than the LCST. This result confirms
the thermo-responsive behavior of TFP NPs even after
copolymerization of PNIPAAm with AH and WBPLP.

Figure 1: Physicochemical characterization of nanoparticles. (A) FTIR spectra of TFP-MNPs, TFP NPs, WBPLP-AH and NIPAAm with arrows indicating the
peaks associated with bonds in polymer backbone and MNPs. (B) TEM images of MNPs, TFP NPs, and TFP-MNPs (all scale bars = 100 nm). (C) Stability of TFP-MNPs
in PBS and 10% FBS at 37°C for 72 hours as measured by changes in nanoparticle size. (D) Phase transition of TFP NPs at LCST (39°C). (E) Temperature-dependent
Dox release kinetics showing higher release at 41°C compared to 37°C and 25°C. (F) Degradation profile of TFP shell on MNPs core showing 86% polymer weight
loss in 13 days.

http://www.ntno.org
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Figure 2: Magnetic properties of nanoparticles. (A) Photographs showing TFP-MNPs suspension in water (left) and recruitment of TFP-MNPs towards a 1.3
T magnet (right). (B) Hysteresis loops of bare MNPs and TFP-MNPs followed the same trend demonstrating their superparamagnetic behavior. (C) T2 weighted MR
images of agarose phantoms containing i. agarose only, ii. TFP NPs, and iii-vi. TFP-MNPs at 0.25, 0.5, 1, and 2 mg/ml concentrations, respectively, showing increasing
negative contrast with increasing iron oxide concentration in agarose phantoms.

Table 1: Physicochemical characterization of nanoparticles
Sample
MNPs
Silane-MNPs
TFP NPs
TFP-MNPs
a

Diameter (nm)
10a
18b
150
135

PDI
0.30
0.35
0.28
0.07

ζ Potential (mV)
-5.1
-21.0
-13.4
-31.0

Iron (%)
100
__
__
75

Size provided by the supplier
Size obtained from TEM analysis (image not shown)

b

Dox loading efficiency in TFP-MNPs was ~90%,
which was higher in comparison to the Dox loading
efficacy in previously synthesized PNIPAAm-AAmAH-based MNPs (82%) by our group. The higher
loading of Dox in TFP-MNPs might be due to either
the interaction between Dox and TFP or more
polymeric swelling of TFP at temperatures below the
LCST while loading Dox. A temperature-dependent
biphasic Dox release was observed (Figure 1E). Dox
was released in a significantly higher amount at 41°C
(temperature > LCST of TFP) compared to that of
37°C and 25°C. There was no difference between Dox
release at 37°C and 25°C, as both the temperatures
were below the LCST of TFP. Since drug release can
also be caused by degradation of the polymer shell,
degradation of the TFP coating on MNPs in DI water
was studied over time. It was observed that the
TFP-MNPs lost 31% polymer weight during the first 4
days (Figure 1F). The degradation rate was then
reduced, which resulted in 37% polymer weight loss
over 13 days. The reduction in the degradation rate
was due to the presence of PNIPAAm and AH
slowing down the hydrolysis of the WBPLP. It is
speculated that the TFP degradation will take longer
than that of WBPLP alone.

Magnetic characterization
The
TFP-MNPs
were
comprised
of
approximately 75% mass of iron (Table 1). Moreover,
in the absence of a magnet, nanoparticles were
suspended and well-dispersed in DI water (Figure
2A). While in the presence of a 1.3 T magnet,

nanoparticles concentrated toward the magnet,
demonstrating the recruitment of nanoparticles via
magnetic targeting. VSM results indicate that the iron
oxide
within
TFP-MNPs
retained
their
superparamagnetic properties and showed a similar
hysteresis loop as bare MNPs (Figure 2B). The
saturation magnetization for bare MNPs and
TFP-MNPs was 63 and 46 emu/g, respectively. A
remanence and coercivity of 6.24 (Mr/Ms) and 59.9
Oe, respectively, was quantified for the TFP-MNPs,
while bare MNPs had a remanence of 8.16 (Mr/Ms)
and coercivity of 75.5 Oe. In addition, agarose
phantoms containing these particles produced a
distinct negative contrast in MRI with greater
negative contrast observed with increasing
concentration of the particles (Figure 2C). These
observations show that the TFP-MNPs possess strong
magnetic properties as well as can potentially act as
MRI contrast agents.

Fluorescence properties
Samples of PNIPAAm-AH, WBPLP, and TFP
NPs were subjected to natural light and UV
illumination in dark. There was no fluorescence from
any of the samples in white light (Figure 3A).
However, a bright fluorescence was observed from
WBPLP and TFP nanoparticles under UV
illumination. The negative control PNIPAAm-AH did
not display any fluorescence contrary to TFP NPs,
which demonstrated fluorescence under UV
illumination, suggesting the origins of TFP NP
fluorescence
from
WBPLP.
Furthermore,
a
temperature-dependent fluorescence study was
performed. The mean fluorescence intensity of TFP
remained the same with increasing temperature
(Figure 3B). The fluorescence photobleaching effect
was also tested at 23°C and 46°C. Even after more
than 10 minutes of continuous laser excitation, no
photobleaching was observed and the fluorescence
intensity remained stable. This indicates that the
fluorescence of the TFP-MNPs will not be affected by
temperature changes.
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Figure 3: Characterization of fluorescence property. (A) Photographs of PNIPAAm-AH, WBPLP and TFP NPs samples in ambient white light and UV light. (B)
Fluorescence intensity of TFP NPs was measured at increasing temperatures and plotted as fluorescence intensity lost as a function of temperature.

In vitro cell studies
Cytocompatibility of TFP-MNPs was tested on
HDFs and PZ-HPV-7 cells. It was observed that the
TFP-MNPs were not toxic at the tested concentrations
for both cell types after 12 hours of incubation (Figure
4A-B). However, after 24 hours of exposure, the
TFP-MNPs showed some level of toxicity towards
HDFs, 27% cell death at 500 µg/ml concentration
compared to the controls. The particles were more
compatible with the PZ-HPV-7 cells, about 12% and
18% cell death was observed at 300 and 500 µg/ml
concentrations, respectively. PZ-HPV-7 cell viability
was above 80% at all concentrations of TFP-MNPs.
The uptake of TFP-MNPs by A431 and G361 skin
cancer cells and LNCaP and PC3 prostate cancer cells
was investigated. A dose-dependent uptake of the
particles was observed in all cancer cell lines
following 2 hours of incubation with the particles
(Figure 4C-D). Higher uptake of TFP-MNPs was seen
in skin cancer cells especially at higher concentrations.
Furthermore, uptake seemed to saturate between
200-300 µg/ml TFP-MNPs concentration in the case of
all the cell lines.
A cancer cell killing study was performed to
determine the in vitro therapeutic efficacy of
Dox-TFP-MNPs with changes in temperature. It could
be seen clearly that in the case of all the cell lines
(A431, G361, PC3) treated with Dox-TFP-MNPs,
greater cell death was observed at 41°C (about 31%,
32% and 44% cell viability, respectively) compared to
the cell death at 37°C (about 83%, 82% and 77% cell
viability, respectively) (Figure 4E). About 30% of the
cell death at 41°C could be attributed to hyperthermia
as seen in the case of the control groups at 41°C.
Minimal cell death was observed on exposure of the
cell lines to empty TFP-MNPs.

In vivo imaging and therapeutic efficacy
In vivo fluorescence imaging was performed after
intra-tumoral injections of nanoparticles. The control
tumors (without nanoparticle injections) did not
display any fluorescence (Figure 5A). A bright
fluorescence was detected from the tumors injected

with TFP NPs, which was then reduced significantly
for TFP-MNPs due to the presence of darker MNPs
(Figure 5B). However, the fluorescence intensity from
TFP-MNPs was significantly higher than that of
hydrophobic BPLP-MNPs. These results show that
the TFP-MNPs can overcome the limitation of
reduced fluorescence from our previously developed
BPLP-MNPs [7].

Magnetic targeting and in vivo MR imaging
Tumor bearing mice were injected with
TFP-MNPs via tail vein injections and the localization
of the nanoparticles was studied in the presence or
absence of a 1.3 T magnetic field. The tumors in both
the magnetic and non-magnetic field treated group
were imaged before and 24 hours post injection. A
negative contrast was observed in the tumors of mice
injected with TFP-MNPs and subsequently treated
with a localized magnetic field, indicating that the
particles were able to be recruited at the tumor site
(Figure 5C). TFP-MNPs administered animals without
the localized magnetic field treatment did not have
any significant darkening in the tumor region.
Analysis of the signal intensity values of the tumors
showed a significant drop (~21%) in signal intensity
in animals injected with TFP-MNPs in the presence of
localized magnetic fields (Figure 5D). The controls
and the groups treated with TFP-MNPs in the absence
of magnetic targeting showed signal intensity drops
of 3.8% and 8.2%, respectively.

In vivo therapeutic efficacy
In vivo therapeutic efficacy of Dox-TFP-MNPs
was studied in animals implanted with B16F10 skin
tumors in the presence of a 1.3 T magnetic field. At the
end of the 15-day study, only an 11-fold increase in
the original tumor volume was observed in animals
treated with Dox-TFP-MNPs in the presence of the
magnetic field (Figure 6). On the other hand, the
control animals given saline injections showed a
61-fold increase in their original tumor volumes. The
animals in the empty TFP-MNPs and free Dox group
showed 59-fold and 21-fold increases in their tumor
volumes, respectively.
http://www.ntno.org
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Figure 4: In vitro cytocompatibility, cellular uptake, and therapeutic efficacy of nanoparticles. (A) Cytocompatibility profiles of TFP-MNPs in normal
human dermal fibroblasts (HDFs) and (B) normal prostate epithelial cells (PZ-HPV-7) as measured by MTS assays. (C) Cellular uptake profiles of TFP-MNPs on LNCaP
and PC3 prostate cancer cells and (D) A431 and G360 skin cancer cells. (E) Cytotoxicity of nanoparticles on skin cancer (A431, G361) and prostate cancer (PC3) cells
at 37°C and 41°C as measured by MTS assays. *p < 0.05.

Discussion
Advancements in cancer diagnosis, treatment
and preventative approaches have led to a drop in
cancer
mortality
rates,
showing
marginal
improvements in survival. Although chemotherapy
has been successful in reducing cancer related deaths,
it often has poor pharmacokinetic profiles in addition
to nonspecific toxicity. Nanoparticle mediated drug
delivery of chemotherapeutics potentially seeks to
eliminate these limitations and have improved
survival outcomes with many clinically developed
nanoparticulate systems demonstrating reduced
systemic toxicity, albeit they have yet to succeed in
improving long-term survival. This warrants the

development of newer nanoscale systems with
improved
functionalities
and
additions
of
multifunctionality into the nanoparticle design. With
the goal to develop a degradable PNIPAAm-based
theranostic drug delivery system, we investigated the
synthesis and characterization of biodegradable TFP
NPs and a core-shell system containing a magnetic
core and TFP shell (TFP-MNPs).
Physicochemical
characterization
of
our
nanoparticles showed well formulated nanoparticles
with excellent colloidal stability in physiological
conditions. The negative surface charges of the
TFP-MNPs potentially repel negatively charged
albumin molecules in the serum, preventing
agglutination
mediated
aggregation
[27].
http://www.ntno.org
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Furthermore, TFP holds the unique characteristics of
thermo-responsiveness from PNIPAAm as well as
fluorescence and degradability from WBPLP. The
increase in LCST (39°C) of the copolymeric
nanoparticles compared to PNIPAAm nanoparticles
(LCST = ⁓32-34°C) can be attributed to the
incorporation of hydrophilic WBPLP-AH [11, 15]. The
sharp volume phase transition of the nanoparticles is
advantageous, enabling a burst release of drugs
followed by a more sustained release, especially at
41°C. The degradation of the polymer shell was
mainly due to hydrolysis of WBPLP, eventually
breaking down PNIPAAm into smaller fragments that
can be potentially cleared in vivo. Interestingly, the
fluorescence from WBPLP was well preserved in the
new copolymer even at higher temperatures. In
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addition, incorporating MNPs into the TFP NPs has
added advantages of magnetic targeting as well as
using these particles as MRI contrast agents. TFP
coating did not affect the superparamagnetic behavior
of MNPs. A small decrease in the saturation
magnetization of TFP-MNPs compared to bare MNPs
can be attributed to the diamagnetic moment of the
polymeric
coating
[23].
Similar
PNIPAAm
copolymeric systems grafted on MNPs have been
shown to have a slight decrease in saturation
magnetization, which has been attributed to the
grafting of polymers to the iron oxide core [28]. The
presence of an iron oxide magnetic core in TFP-MNPs
renders them the ability to dephase proton spins
causing a reduction in MR signal intensity, making
them useful as T2 contrast agents [29].

Figure 5: In vivo imaging and magnetic targeting of nanoparticles. (A) Fluorescent images of prostate cancer tumors in mice after intra-tumoral injection of
nanoparticles. (B) Relative fluorescence intensities from the panel A (*p < 0.05). (C) T2-weighted MR images of prostate tumors in mice before and 24 hours after i.v.
injection of nanoparticles in the presence or absence of an external magnet. The red arrow indicates negative contrast generated due to accumulation of TFP-MNPs.
(D) MRI signal intensity drop in prostate cancer tumors 24 hours post-injection from the panel C (*p < 0.05).

Figure 6: In vivo therapeutic efficacy of nanoparticles. Skin cancer B16F10 tumor volume fold increase in mice after i.v. injection of nanoparticles in the
presence of 1.3 T external magnet (*p < 0.05).
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Overall, in vitro data including cell studies
further highlights the potential of TFP-MNPs as a
drug delivery vehicle for solid tumors. Surface
properties of nanoparticles play a major role in
cellular toxicity and uptake. The negatively charged
polymer
shell
is
potentially
alleviating
MNP-mediated toxicity [30, 31] by preventing MNP
interactions with the cell membrane. Further, the
differential uptake of TFP-MNPs in prostate and skin
cancer cells is in agreement with our previous studies
on the uptake of BPLP-MNPs and WBPLP-MNPs in
PC3 and LNCaP cell lines where the more hydrophilic
WBPLP-MNPs showed significant preferential uptake
into PC3 cell lines relative to LNCaP cell lines [7]. It
has been shown that MNPs coated with proteins
exhibited preferential cellular uptake in different
cancer cell lines, even in isogenic cell lines [32]. The
preferential uptake of TFP-MNPs by PC3 and G361
cancer cell lines, which have higher metastatic
potential than LNCaP and A431 cell lines, indicates
the utility of TFP-MNPs to target more aggressive
kinds of cancers [33]. Further, Dox-TFP-MNPs were
effective in killing cancer cells under simulated
hyperthermia conditions. The insignificant difference
in cell killing between free Dox and Dox-TFP-MNPs at
41°C across all cell lines was potentially due to the fact
that free Dox experiences increased cellular uptake at
temperatures exceeding 40°C as well as has the ability
to be actively cytotoxic without entering cells [34, 35].
The cell death in untreated controls and empty
TFP-MNPs group at 41°C was attributed to the
negative effects of hyperthermia [36, 37].
Our preliminary in vivo data showed the
dual-imaging, magnetic targeting, and therapeutic
efficacy potential of the TFP-MNPs. A significantly
higher fluorescent intensity in TFP NPs treated
groups compared to TFP-MNPs was possibly due to
the presence of a darker iron oxide core, which has
been shown to quench fluorescence on contact with
various fluorescent materials [38-40]. The quenching
of fluorescence was quantitatively lesser in
TFP-MNPs compared to MNPs coated with the
fluorescent hydrophobic BPLP polymer. We believe
this difference is due to the nature of the polymer
interaction with the MNP surface. The covalent
bonding of TFP to the MNPs holds the polymer shell
in place compared to the physical adsorption of BPLP
on the MNP surface, increasing the possibility of
BPLP shell/fragments separating from MNPs.
Further, magnetic targeting played a key role in
recruiting TFP-MNPs at the tumor site in sufficient
doses to be therapeutically effective. The use of
magnetic targeting to deliver drugs to tumors relies
on the physical force of magnetic fields to partition
the magnetic carrier from the arteriole wall into the
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tumor region resulting in increased drug localization
and retention even after the subsequent removal of
the applied magnetic field [18, 41]. Similar drug
carrying magnetic nanocarriers using magnetic
targeting have been shown effective in delivering
various agents like mitoxantrone, epirubicin and
doxorubicin in tumor bearing rats and cause tumor
remission in various cancer models [42-44].
Our study has a few limitations. We have used
different cell lines from two different cancer types for
in vitro experiments and two different animal models
for in vivo experiments. While our TFP-MNPs are not
tested extensively on one particular disease, we
intended to show the theranostic feasibility and
effectiveness of our nanoparticles on different solid
tumor types. In addition, in the current age of active
(receptor-mediated) targeting of nanoparticles, our
nanoparticle design lacks this advantageous element.
In the future, we plan to conjugate TFP-MNPs with
targeting moieties and cell penetrating peptides,
giving the nanoparticle system specificity towards
solid tumors and explore a targeted site-specific
delivery. Nonetheless, we could show the
effectiveness of TFP-MNPs in controlling tumor
growth by using magnetic targeting as a standalone
approach. Our results demonstrated a great potential
of TFP-MNPs as a theranostic platform technology.
The development of TFP-MNPs will not only
overcome the drawbacks of the long-term toxicity of
quantum dots and poor photostability of organic
dyes, but also allow simultaneous diagnosis and
treatment of cancers in a single setting. In the future,
these nanoparticles with the use of alternating
magnetic fields, could be used for producing heat for
hyperthermia therapy and temperature-controlled
drug release, enabling combinational treatment
options [23, 24]. Therefore, we think that TFP-MNPs
can serve as an effective platform for future
development of theranostic nanoparticles.

Conclusion
We developed a novel TFP and its core-shell
structure with magnetic nanoparticles - TFP-MNPs.
TFP-MNPs maintained excellent colloidal stability
and had a degradable shell that eliminates long-term
toxicity concerns and bypasses the size limitations for
in vivo clearance in the traditional nanoparticle
designs.
The
thermo-responsiveness
of
the
PNIPAAm-AH was preserved after copolymerization
with WBPLP to form TFP. The imaging studies
showed optical and MR imaging capabilities using
TFP-MNPs. Finally, the cytocompatible nanoparticles
magnetically recruited to the tumor region delivered
therapeutic doses of doxorubicin to inhibit tumor
growth. We showed multifunctional capabilities of
http://www.ntno.org
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TFP-MNPs including multimodal imaging, magnetic
targeting, and thermo-responsive drug release,
making TFP-MNPs an excellent platform of
theranostic systems for future cancer diagnosis and
therapy.
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